期刊： INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022; 115 (4)
Vedolizumab, an immunosuppressive drug that acts locally on the gastrointestinal tract, is mainly used for the treatment of inflammatory bowel disease......
期刊： INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022; 115 (5)
We conducted a prospective, three-center, observational study in Japan to evaluate the prevalence of seropositivity and clinically protective titer af......
期刊： INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022; 115 (6)
This study examined the prognostic impact of erythroblast predominance (EP) in 61 patients with myelodysplastic syndromes (MDS) (n = 51) or acute myel......
期刊： INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022; 116 (3)
There have recently been a few case reports of cutaneous T-cell lymphomas following treatment of atopic dermatitis with dupilumab, which works binding......
期刊： INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022; 116 (2)
An 8-year-old Japanese boy with no underlying disease presented with severe intramuscular hematoma of the hip, and was admitted for a disseminated int......
期刊： INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022; 116 (4)
Background In Japan, anagrelide has been approved for use in patients with essential thrombocythemia. Here, the safety and efficacy of anagrelide was ......
期刊： INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022; 116 (4)
Objectives The Immune Thrombocytopenia (ITP) Life Quality Index (ILQI) is a 10-item patient-reported outcome (PRO) measure developed in US-English to ......
期刊： INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022; 116 (5)
Genetic diagnostic methods for evaluation of chimerism after HSCT, such as STR-PCR and XY-FISH, have limited sensitivity. When donor chimerism is in t......
期刊： INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022; 115 (1)
Up to 25% of patients with classical Hodgkin lymphoma (cHL) and a negative interim PET/CT will progress. Unfortunately, there are few published studie......
期刊： INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022; 115 (2)
Juvenile myelomonocytic leukemia (JMML) is a pediatric hematological malignancy with a poor prognosis. Although several case series have been publishe......
期刊： INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022; 115 (3)
Background Many studies have investigated treatment-related sequelae in Hodgkin's lymphoma (HL) in high-prevalence areas, but very few have been condu......
期刊： INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022; 115 (4)
Emicizumab reduces bleeding events in patients with severe hemophilia A (HA). The coagulation potential of emicizumab at a clinical dose appears to co......
